Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

07-29 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
20/06/25	79.06 $	-0.29%	34,052,298
18/06/25	79.29 $	+1.29%	23,803,430
17/06/25	78.28 $	-3.31%	14,040,588
16/06/25	80.96 $	-0.92%	12,569,440
13/06/25	81.71 $	-0.13%	14,550,530

Delayed Quote Nyse, June 20, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

79.06USD

Average target price

101.79USD

Spread / Average Target

+28.75%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 21:00:36 20/06/2025 BST			5-day change	1st Jan Change
79.06 ^USD	-0.29%		-3.24%	-20.53%

06-18	Kennedy's new US vaccine panel to discuss measles shot for children	RE
06-18	Kennedy's new US vaccine panel to discuss measles shot for children	RE

Capitalization	199B 172B 162B 147B 273B 17,194B 307B 1,921B 735B 7,877B 745B 729B 28,955B	P/E ratio 2025 *	10.1x	P/E ratio 2026 *	9.02x
Enterprise value	214B 186B 175B 159B 294B 18,523B 331B 2,069B 792B 8,486B 802B 785B 31,193B	EV / Sales 2025 *	3.29x	EV / Sales 2026 *	2.93x
Free-Float	70.67%	Yield 2025 *	4.07%	Yield 2026 *	4.27%

Kennedy's new US vaccine panel to discuss measles shot for children	06-18	RE
Kennedy's new US vaccine panel to discuss measles shot for children	06-18	RE
CDC's vaccine advisory committee to vote on RSV, flu shots	06-18	RE
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer	06-18	CI
Merck: Phase 3 trial in prostate cancer	06-18	CF
Merck Doses First Patient in Phase 3 Trial of Prostate Cancer Drug Candidate	06-18	MT
Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May	06-17	MT
Trump Administration to Consider Pharma Advertising Crackdown	06-17	MT
Trump Administration to Consider Pharma Advertising Crackdown, Bloomberg reports	06-17	MT
Merck Manuals Launches AI-Powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources	06-16	CI
Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…	06-13
Merck: FDA approves Keytruda for head and neck cancer	06-13	CF
FDA Approves Merck's Anti-PD-1 Therapy	06-13	CI

DBS Bank Adjusts Price Target on Merck & Co. to $96 From $100, Maintains Buy Rating	06-02	MT
Berenberg Adjusts Price Target on Merck & Co. to $100 From $115, Maintains Buy Rating	05-20	MT
Analyst recommendations: AbbVie, KKR, Merck, Toast, Uber…	05-14
Citigroup Downgrades Merck & Co. to Neutral From Buy, Adjusts Price Target to $84 From $115	05-14	MT
Guggenheim Adjusts Merck & Co.'s Price Target to $108 From $115	04-30	MT

Merck & Co., Inc. Share Price

Equities

MRK

US58933Y1055

Pharmaceuticals

Valuation: Merck & Co., Inc.

Chart: Merck & Co., Inc.

Latest news: Merck & Co., Inc.

Last Transcript: Merck & Co., Inc.

Analysts' recommendations: Merck & Co., Inc.

Press Releases: Merck & Co., Inc.

News in other languages: Merck & Co., Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Merck & Co., Inc.

ETFs: Merck & Co., Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients	06-19	AQ
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer	06-18	BU
Merck - FDA Approves KEYTRUDA for PD-L1+ Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy	06-16	AQ
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent	06-13	BU
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs	06-12	BU

Merck : Un premier patient traité chez Merck dans un essai de phase 3	06-18
Merck : essai de phase 3 dans le cancer de la prostate	06-18
Merck : la FDA approuve Keytruda en cancer de la tête et cou	06-13
Mariage entre BioNTech et CureVac dans la recherche contre le cancer	06-12
Merck : essai de phase 3 pour le vaccin contre la dengue	06-12

1 day	-0.29%
1 week	-3.24%
Current month	+2.89%
1 month	+1.40%
3 months	-16.54%
6 months	-19.37%
Current year	-20.53%

1 week	77.1	81.35
1 month	75.4	82.44
Current year	73.31	102.97
1 year	73.31	134.63
3 years	73.31	134.63
5 years	70.89	134.63
10 years	45.69	134.63

Manager	Title	Age	Since
Robert Davis CEO	Chief Executive Officer	58	30/06/2021
Caroline Litchfield DFI	Director of Finance/CFO	56	31/03/2021
Dave Williams CTO	Chief Tech/Sci/R&D Officer	56	31/07/2020

Director	Title	Age	Since
Tom Glocer BRD	Director/Board Member	64	26/11/2007
Patricia Russo BRD	Director/Board Member	72	31/08/1995
Robert Davis CHM	Chairman	58	30/11/2022

Name	Weight	AuM	1st Jan change
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	14.34%	378 M€	-0.92%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	5.61%	21 M€	+0.15%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MERCK & CO., INC.	-0.29%	-3.24%	-39.03%	-6.57%	199B
ELI LILLY AND COMPANY	-2.84%	-6.91%	-13.91%	+162.20%	685B
JOHNSON & JOHNSON	-0.62%	-4.65%	+1.36%	-11.61%	360B
NOVO NORDISK A/S	-2.58%	-7.83%	-52.12%	+25.00%	326B
ABBVIE INC.	-0.10%	-3.02%	+7.65%	+34.00%	327B
ROCHE HOLDING AG	-0.27%	-3.86%	+3.72%	-14.84%	255B
NOVARTIS AG	-0.34%	-2.34%	+0.59%	+19.15%	228B
ASTRAZENECA PLC	-1.52%	-5.41%	-16.18%	+3.36%	217B
AMGEN INC.	-0.10%	-2.00%	-6.63%	+23.27%	156B
PFIZER, INC.	+0.38%	-2.32%	-13.59%	-48.48%	136B
Average	-0.17%	-3.99%	-12.81%	+18.55%	288.83B
Weighted average by Cap.	-0.12%	-4.60%	-12.67%	+42.65%

	2025 *	2026 *
Net sales	65B 56.38B 53.11B 48.26B 89.27B 5,630B 101B 629B 241B 2,579B 244B 239B 9,480B	68.56B 59.47B 56.01B 50.9B 94.16B 5,938B 106B 663B 254B 2,720B 257B 252B 9,999B
Net income	19.92B 17.28B 16.28B 14.79B 27.36B 1,725B 30.83B 193B 73.77B 790B 74.76B 73.16B 2,906B	21.96B 19.05B 17.94B 16.3B 30.16B 1,902B 33.99B 212B 81.32B 871B 82.41B 80.65B 3,203B
Net Debt	15.34B 13.31B 12.54B 11.39B 21.07B 1,329B 23.74B 148B 56.81B 609B 57.57B 56.35B 2,238B	2.13B 1.84B 1.74B 1.58B 2.92B 184B 3.29B 20.56B 7.87B 84.33B 7.98B 7.81B 310B